NCT01515345

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,008 (actual)
• Sponsor: Kaiser Franz Josef Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer).

Detailed description

Depending on the clinical presentation patients are treated according to standard operating procedures in our department. The earliest, 12 hours after an initial clopidogrel-loading dose (600mg)"on-treatment" platelet reactivity will be determined by Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer), a point of care assay. In case of high residual platelet reactivity (i.e. ≥ 50U), patients are switched according to a therapeutic algorithm to either prasugrel (Efient®), or in case of contraindication (i.e. stroke) to ticagrelor (Brilique®), or in case of contraindication (intracranial hemorrhage) reloaded with clopidogrel.

Conditions

• Platelet Inhibition
• Coronary Stent Implantation

Interventions

Type	Name	Description
DRUG	prasugrel or ticagrelor	prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
DRUG	Clopidogrel	clopidogrel 75mg od for 12 month

Timeline

• Start date: 2011-07-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2012-01-24
• Last updated: 2017-04-25
• Results posted: 2013-05-01

Locations

1 site across 1 country: Austria